Description
The Model 170 Next Generation Pharmaceutical Impactor (NGI) is a high-performance, precision, particle-classifying cascade impactor for testing metered-dose, dry-powder, and similar inhaler devices.
Close Information
MSP developed this impactor in conjunction with a 15-member consortium of pharmaceutical companies (Next Generation Impactor Consortium).
APPLICATIONS
Substantial user-involvement in the design process has resulted in a combination of aerodynamic design principles and user-friendly operation. A removable set of collection cups minimizes the time between inhaler tests. Other time-saving features include the absence of a final filter and of inlet O-rings. The NGI has been tested by 15 pharmaceutical companies in the NGI Consortium.
FeaturesDesigned for productivity